Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma: early-phase trial registry
1 of 6 indexed FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma: 6 US clinical trials tracked, 1 recruiting.
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition figo-grade-1-endometrial-endometrioid-adenocarcinoma
OPEN 1 | RECR 17% | LATE 0 | EARLY 3 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma research.
M.D. Anderson Cancer Center accounts for 2 of 6 trials (33.3%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma enrolment sits around 102 participants.
Median target enrolment is 102 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
Mayo Clinic
NCT06689956
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
M.D. Anderson Cancer Center
NCT04604613
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
M.D. Anderson Cancer Center
NCT02397083
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
National Cancer Institute (NCI)
NCT05538897
Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas
Mayo Clinic
NCT06213571
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
National Cancer Institute (NCI)
NCT04092270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma condition card totals 6 registered trials; most-linked intervention Biospecimen Collection; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.